Table 1:
Changes in immune response observed in patients treated with locoregional therapies.
| No. of reference | Locoregional Treatment (TRX) | Immune outcome measurements | Source of immune measurements tumor (T), peripheral blood (P) | Number of patients | Year of publication |
|---|---|---|---|---|---|
| (38) | MWA | Th17, CD3, CD4, CD8, Tregs | P | 30 HCC | 2018 |
| (39) | MWA | CD3, CD4, CD8, CD4+ CD25+ Tregs, and CD16+ CD56+ NK | P | 45 HCC | 2017 |
| (40) | RFA | APC maturation and function (in vitro assay for tissues before and after ablation) | T, P | 19 | 2008 |
| (41) | RFA | tumor-associated antigen (TAA)-derived peptides | P | 69 HCC | 2013 |
| (43) | RFA | MDSCs | P | 123 HCC patients, 33 received RFA | 2013 |
| (46) | TACE | Cell death sera markers: HMGB1, sRAGE, DNase | P | 50 HCC, 71 procedures | 2012 |
| (49) | RFA/TACE/Surgical resection | Glypican-3 -specific CTLs | P | 9 RFA, 9 TACE, 9 Surgical resections | 2012 |
| (54) | RFA | Th1 (IL-2, TNF-α, IFN-γ), Th2 (IL-4, IL-6, IL-10) | P | 26 HCC, 25 healthy | 2017 |
| (55) | RFA | Immune potentiating antigens in the serum, Ficolin-3 | P | 57 HCC | 2018 |
| (56) | TACE | IL12p70, IFN-γ, IL-17A, IL-2, IL-10, IL-9, IL-22, IL-6, IL-13, IL-4, IL-5, IL-1β, and TNF-α | P | 83 HCC, 33 healthy | 2013 |
| (57) | TACE | CD4 (Th1, Th17 and Treg cells), CD8, NK, NKT, IL-2, IL-4, IL-6, IL-10, IL17A, IFN-γ, and TNF-α | P | 28 stage I HCC, 51 stage III, 20 healthy | 2013 |
| (58) | TACE | CD4, CD8, Treg, IL-35 | P | 47 HCC, 15 healthy | 2015 |
| (59) | Bland embolization | Th1, Th2, Treg | P | 5 HCC | 2016 |
| (60) | Cryo+TACE | CD3/CD4, CD4/CD8, NK | P | 32 TACE, 31 Cryo, 35 Cryo+TACE | 2015 |
| (50) | Y90 | In depth phenotyping | T, P | 41 | 2018 |
| (51) | Y90 | IL10, IFN-γ, CD3, CD4, CD8, B, NK, cd45R0 | P | 25 | 2018 |
| (52) | Y90 | IL6,8, TNF-α, Nitrotyrosin, malondialdehyde | P | 14 | 2014 |
| (53) | Y90 | IL1,2,4,6,8, TNF-α, IFN-γ | P | 12 HCC (total of 34) | 2017 |